SEC Comment Letter 0000000000-25-005529 to Avenir Wellness Solutions, Inc. (CIK 0001643301)
Avenir Wellness Solutions, Inc. (CIK 0001643301)
Date: May 23, 2025 · CIK: 0001643301 · Accession: 0000000000-25-005529
AI Filing Summary & Sentiment
Letter
May 23, 2025 Joel Bennett Chief Financial Officer Avenir Wellness Solutions, Inc. 5805 Sepulveda Blvd Suite 801 Sherman Oaks, CA 91411 Re:Avenir Wellness Solutions, Inc. Form 10-K for the Year Ended December 31, 2022 Form 10-Q for the Period Ended September 30, 2023 Dear Joel Bennett: We issued comments on the above captioned filing on April 11, 2024. On May 2, 2025, we issued a follow-up letter informing you that comment(s) remained outstanding and unresolved, and absent a substantive response, we would act consistent with our obligations under the federal securities laws. As you have not provided a substantive response, we are terminating our review and will take further steps as we deem appropriate. These steps include releasing publicly, through the agency's EDGAR system, all correspondence, including this letter, relating to the review of your filing, consistent with the staff's decision to publicly release comment and response letters relating to disclosure filings it has reviewed. Please contact Christine Torney at 202-551-3652 or Kevin Vaughn at 202-551-3494 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
May 23, 2025
Joel Bennett
Chief Financial Officer
Avenir Wellness Solutions, Inc.
5805 Sepulveda Blvd
Suite 801
Sherman Oaks, CA 91411
Re:Avenir Wellness Solutions, Inc.
Form 10-K for the Year Ended December 31, 2022
Form 10-Q for the Period Ended September 30, 2023
Dear Joel Bennett:
We issued comments on the above captioned filing on April 11, 2024. On May 2,
2025, we issued a follow-up letter informing you that comment(s) remained outstanding and
unresolved, and absent a substantive response, we would act consistent with our obligations
under the federal securities laws.
As you have not provided a substantive response, we are terminating our review and
will take further steps as we deem appropriate. These steps include releasing publicly,
through the agency's EDGAR system, all correspondence, including this letter, relating to the
review of your filing, consistent with the staff's decision to publicly release comment and
response letters relating to disclosure filings it has reviewed.
Please contact Christine Torney at 202-551-3652 or Kevin Vaughn at 202-551-3494
with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences